Remington E. Schmidt
YOU?
Author Swipe
View article: Meta‐Analysis & Review of Blood Neurofilament Light Performance in Diagnosis of All‐Cause Dementia
Meta‐Analysis & Review of Blood Neurofilament Light Performance in Diagnosis of All‐Cause Dementia Open
Background NfL is a non‐specific biomarker that elevates in the presence of axonal damage. In the blood, it has recently been explored as a potential test in evaluating the presence or absence of dementia. Method A systematic review and me…
View article: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD) Open
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the preci…
View article: Joint Public Review: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Joint Public Review: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD) Open
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the preci…
View article: Author response: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Author response: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD) Open
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the preci…
View article: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD) Open
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the preci…
View article: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD) Open
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the preci…
View article: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD) Open
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the preci…
View article: Germline <i>cis</i> variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ( <i>DPYD</i> )
Germline <i>cis</i> variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ( <i>DPYD</i> ) Open
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the preci…
View article: A Robust Bayesian Approach to Bulk Gene Expression Deconvolution with Noisy Reference Signatures
A Robust Bayesian Approach to Bulk Gene Expression Deconvolution with Noisy Reference Signatures Open
Background Differential gene expression in bulk transcriptomics data can reflect change of transcript abundance within a cell type and/or change in the proportion of cell types within the sample. Expression deconvolution methods can help d…
View article: Additional file 5 of An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes
Additional file 5 of An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes Open
Additional file 5. Predicted mediators of JunD influence on CRC progression. Table 1. contains the model-predicted targets of JunD (top 500 RPOR scores in down-analysis) that were differentially expressed upon knock-down of JunD (p-value <…
View article: Additional file 2 of An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes
Additional file 2 of An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes Open
Additional file 2. Gene set characterization. Gene set characterization of the DE genes between early and late stages. The downregulated genes are significantly enriched for cancer-related gene signatures from mSigDB.
View article: Additional file 4 of An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes
Additional file 4 of An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes Open
Additional file 4: Table S1. List of HCT116 TFs and their corresponding files obtained from ENCODE portal ( https://www.encodeproject.org/ ). Table S2. Interpretations of the different combinations of signs of TF and histone mark change we…
View article: Additional file 3 of An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes
Additional file 3 of An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes Open
Additional file 3. Annotated list of genes with SNVs that exhibited significant shifts in alternative allele frequency between M0 and M6.